MOCS1

Across TCGA pan-cancer cohorts, MOCS1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MOCS1 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MOCS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MOCS1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where MOCS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.576	1.000	.005	32	view →
PDAC	OS	Median	All	0.931	0.650	.002	30	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.789	.020	24	view →
COAD	DFS	Median	III,IV	0.733	1.000	.038	6	view →
HNSC	DFS	Median	III,IV	0.728	0.503	.012	4	view →
UCEC	OS	Quartile	All	0.868	1.000	.048	2	view →
LSCC	OS	Tertile	III,IV	0.780	0.380	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MOCS1–LUAD (DFS)

Open the LUAD breakdown →